ADC Therapeutics falls sharply on blood cancer drug safety concerns in Phase 3 trial
#ADC Therapeutics shares fell sharply after a Phase 3 study of its lymphoma drug Zynlonta raised serious safety concerns.
#The stock fell to approximately $1.50 on June 4, 2026, following the trial announcement on June 3.
#The trial showed higher rates of serious adverse events and Grade 5 events in the Zynlonta arm, which analysts highlighted as potentially difficult for physicians, patients, and regulators to accept.
S&P Global denies SpaceX fast-track entry into the S&P 500 index
#S&P Global announced on Thursday it will not modify its rules to allow unprofitable companies quick entry into the S&P 500.
#The decision locks out SpaceX, which is set to list next week at a $1.75 trillion valuation but posted a $5 billion loss in 2025.
#This contrasts with the rival Nasdaq index, which changed its rules to allow easier access for megacaps, though float-adjusted weighting will limit SpaceX's initial index weight to less than 1% of the Nasdaq-100.
#Vivakor Inc. shares fell sharply on Thursday following announcement of a crude oil transaction valued at $108 million annualized.
#The stock declined 36.0% to close at $0.845 on a massive volume of 34.48 million shares, which is 416 times its recent daily average.
#The sharp drop coincides with the deal announcement, though the company faces significant financial headwinds including recent forbearance agreements and dilutive financing.